Association of COX-inhibitors with cancer patients’ survival under chemotherapy and radiotherapy regimens: a real-world data retrospective cohort analysis
Selective COX-2 inhibition significantly reduced mortality and emergency department visit rates. Further clinical trials are needed to determine the optimal conditions for indication of coxibs as anti-inflammatory adjuvants in cancer treatment.
Authors
- Wen‐Jan Tuan (ORCID: https://orcid.org/0000-0003-3939-8979)
- Maria Del Pilar Estevez-Diz (ORCID: https://orcid.org/0000-0003-3176-9747)
- Roger Chammas (ORCID: https://orcid.org/0000-0003-0342-8726)
- Lucas E. Flausino (ORCID: https://orcid.org/0000-0002-2800-0374)
- Isabella Nevoni Ferreira
Institutions
- Instituto do Câncer do Estado de São Paulo (BR)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Department of Public Health (MM)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-13
- DOI
- https://doi.org/10.3389/fonc.2024.1433497
- Citations
- 5
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 2.24
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico